{"protocolSection":{"identificationModule":{"nctId":"NCT02384330","orgStudyIdInfo":{"id":"A-38-52120-188"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke","officialTitle":"Cost Determination Study For Different Botulinum Toxin A Preparations In The Treatment Of Upper Limb Spasticity Post-Stroke In Portugal","acronym":"P_Dysport_CS"},"statusModule":{"statusVerifiedDate":"2019-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-16","type":"ACTUAL"},"completionDateStruct":{"date":"2017-03-16","type":"ACTUAL"},"studyFirstSubmitDate":"2015-03-04","studyFirstSubmitQcDate":"2015-03-04","studyFirstPostDateStruct":{"date":"2015-03-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-01-04","lastUpdatePostDateStruct":{"date":"2019-01-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal.\n\nIt will consider the three most used locally available brands of botulinum toxin A which show similar efficacy and safety profiles thus making it relevant to understand if choosing between one or another brand can depend directly on economic factors.\n\nThe study will estimate direct and indirect drug-associated costs as determinant variables for the price of each drug and the standard drug dose used in clinical practice.","detailedDescription":"A comparison will be performed between direct costs associated with each therapeutic strategy and cost analysis assuming that quality of life values may be different between patients treated with each treatment."},"conditionsModule":{"conditions":["Upper Limb Spasticity Post-Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"OTHER"},"enrollmentInfo":{"count":57,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dysport® (abobotulinumtoxinA)","description":"Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines."},{"label":"Botox® (onabotulinumtoxinA)","description":"Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines."},{"label":"Xeomin® (incobotulinumtoxinA)","description":"Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Estimate the cost of botulinum toxin utilization","description":"Direct resource utilization and costs of upper limb spasticity patients treated with BoNT-As, by product","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Number of work days missed due to spasticity","description":"Assessment of Absenteeism /loss of productivity","timeFrame":"12 months"},{"measure":"Carer time needed for patient assistance","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with post-stroke upper limb spasticity\n* Patients currently being treated with Dysport®, Botox® or Xeomin®\n* Patients stabilized from a therapeutic point of view - with no switches of treatment in at least the 2 last administrations\n* Patients who gave their written informed consent to participate.\n\nExclusion Criteria:\n\n* Not applicable.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Hospital ambulatory patients","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Centro de Medicina de Reabilitação de Alcoitão","city":"Alcabideche","zip":"2649-506","country":"Portugal","geoPoint":{"lat":38.73366,"lon":-9.40928}},{"facility":"C. H. A. - Hospital de Faro","city":"Faro","zip":"8000-386","country":"Portugal","geoPoint":{"lat":37.01937,"lon":-7.93223}},{"facility":"C. H. T. M. A. D. - Unidade Hospitalar de Vila Real","city":"Vila Real","zip":"5000-508","country":"Portugal","geoPoint":{"lat":41.30062,"lon":-7.74413}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}